Arsenic Trioxide for Structural p53 Mutations

Inclusion Criteria:

* Malignant solid tumors diagnosed histologically;
* Solid tumor patients have no any standard choice after multiple line of therapy;
* Next-generation Sequence showed TP53 mutation;
* Expected survival ≥ 1 month;
* ECOG / PS score: 0-2, and the main organ function to meet the following criteria: HB ≥ 90g / L, ANC ≥ 1.5 × 109 / L, PLT ≥ 80 × 109 / L,BIL \<1.5 times the upper limit of normal (ULN); Liver ALT and AST \<2.5 × ULN and if liver metastases, ALT and AST \<5 × ULN; Serum Cr ≤ 1 × ULN, endogenous creatinine clearance ≥50ml/min
* normal cardiac function
* obtain informed consent

Exclusion Criteria:

* Patient still has standard treatment therapy based on NCCN guidance;
* Patient can not comply with research program requirements or follow-up;
* woman who are pregnant or breastfeeding;
* allergic to any drug in protocol or with contraindications;
* cannot understand or obey the protocol;
* with a history of allergies or intolerability;
* participate in other clinical trials meanwhile;
* any situations that hinder trial existed;